United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting (PREF-NET)

Ipsen

Status: Completed

Conditions: Neuroendocrine Tumours (NET)

Study type: Observational

Funder types: Industry

Identifiers

NCT04649580

A-GB-52030-394

Details and patient eligibility

About

The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a diagnosis of GEP-NETs
• Patients on prescribed lanreotide Autogel®;
• Patients who have switched from hospital to homecare administration setting at least 2 months ago
• Patients judged to be on a stable dose; 120mg for tumour control or >1 injection at same dose for symptom control

Exclusion criteria

• Patients who decline or lack capacity to consent to participate in the study

Trial design

80 participants in 2 patient groups

Online Survey

One-to-one interviews